2001•University of Groningen research database (University of Groningen / Centre for Information Technology)Requires access

The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantel cell lymphomas (MCL) - Results of a prospective randomized comparison of the German low grade study group (GLSG).

Hiddemann, W, Roswitha Forstpointner, F. Fiedler, Martin Gramatzki, Bernd Dörken, H.J. Illiger, Michael Kneba, M. Pfreundschuh, Parsold, R, Parwaresch, R, Martin Dreyling, Unterhalt, M

Open publisher page 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Fludarabine, Mitoxantrone, Rituximab, Cyclophosphamide, Medicine, Chemotherapy, Refractory (planetary science), Oncology